Foundation Medicine — Merger or Acquisition (January 2015)
20 slides from Foundation Medicine's merger presentation, Jan 12, 2015
Slide 1: Schedule 14A Proxy Statement - Foundation Medicine, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy
Slide 2: Filing fee and previous filing information
(5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or t
Slide 3: Filed by Foundation Medicine, Inc. Pursuant to Rule 14a-12
Filed by Foundation Medicine, Inc. Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Foundation Medicine, Inc. Commission File No.: 001-36086 Set forth below is a copy of a press release issued by Foundation Medicine, Inc. on January 12, 2015 and a copy of the slide
Slide 4: Foundation Medicine Enters a Broad, Strategic Collaboration with Roche
NEWS RELEASE Foundation Medicine Enters a Broad, Strategic Collaboration with Roche in the Field of Molecular Information in Oncology —Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer— • Roche to acquire a majority interest
Slide 5: Novel approaches to R&D, Product Development and Commercialization
“We are excited to announce this strategic collaboration with Roche, which will help accelerate our business, and importantly, represents significant potential for individuals with cancer around the world. We believe that putting molecular information at the center of cancer care will help transform
Slide 6: Closing conditions, board approval and support agreements
The completion of Roche’s direct investment in Foundation Medicine, and the successful outcome of the tender offer, as well as the execution of the collaboration agreements are all cross-conditional subject to Foundation Medicine shareholder approval, clearance under the Hart-Scott-Rodino Antitrust
Slide 7: About Roche
About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology
Slide 8: Important Information and Where to Find It
Important Information and Where to Find It The tender offer described in this press release (the “Offer”) has not yet commenced, and this press release is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Foundation Medicine or any other securities
Slide 9: Foundation Medicine & Roche Join Forces to Transform Molecular Information in Oncology
Foundation January 12, Medicine 2015 & Roche Join Forces to Transform the Field of Molecular Information in Oncology
Slide 10: Forward-Looking Statements and Important Information
Forward-Looking These implementation including detailed Important The Medicine United Statement transmittal INVESTORS PROXY holders for Foundation SEC in Medicine’s charge 2©2015 the the tender rules solicitation, presentation tender from States Foundation may in STATEMENT, or the Information on to
Slide 11: Strategic Partnership: Transforming Oncology
Strategic The Both Accelerate Standardize Commercialize Develop 3©2015 strategic companies Foundation and Partnership: market the clinical commercialize collaboration molecular diagnosis, seek adoption Medicine, sample to Transforming accelerate tests treatment aims analysis of a Inc. universal and
Slide 12: Strategic Partnership: Enhancement for Foundation Medicine
Strategic Enhancement 5-year New Expanded Enhanced Acceleration Maintains Additional Immediate 4©2015product commitment Foundation Partnership: market commercialization independent value capital of development ofglobal molecular todevelopment and Medicine, existing toTransforming broad cash access i
Slide 13: Foundation Medicine milestones and growth
Ensuring $18/share IPO Market FoundationOne Incorporation $505mm Foundation 2010 Medicine Clinical 5©20152011 Foundation Cap Tests Long-Term Enhanced 2012 Launched ofReported: ofReleased 2013 FoundationOne Medicine, Platform 2014 Heme 1,614 2015 Launched Inc. 9,095 Leadership FoundationOne | Confide
Slide 14: Bringing Together Two Industry Leaders
Bringing Industry Most Entrepreneurial ~120 Global Leader Combining 6©2015 year advanced leader Foundation inpioneer Together personalized history Forces inand organization oncology inand Two in Medicine, the continuously Oncology experience transformation healthcare Industry – breadth combining Inc
Slide 15: Unique Independent Structure and Self-Governance
Unique Independent Self-Governance Allocation Hiring Nimble Free Meaningfully Joint R&D 5-year Acceleration Expansion Option Commercial Coordination US Broadened Large Entrepreneurial ©2015 support to Efforts Collaboration Company commitment decisions Foundation to continue Transaction infrastructur
Slide 16: Multi-Element R&D Collaboration Economics
Multi-Element, Molecular Sample Economics Clinical ctDNA Capitalize Multiple Cancer Leverage R&D Right Companion Approved Accelerated Development IVD Pursue Encompasses FMI ©2015Kits and funding, toaFoundation immunotherapy platform profiling Product commercialize future incentive Roche Roche and on
Slide 17: Major Commercial Advantages: U.S. and Outside U.S.
Majorto Education U.S. Genentech Outside FoundationOne™, Leverage Roche FMI ©2015conducts Commercial exclusive commitment Foundation develop be U.S. Roche compensated support representatives option testing education local rights to program FoundationOne Medicine, Advantages to co-promote from affili
Slide 18: Financial Impact
Financial Roche Share >$150 Sample Throughput Continued Additional All ©2015 elements price to will million Foundation throughput acquire Impact growth cash tender also represents and ofinthis invest and milestones additional afor in majority Medicine, and transaction in-kind associated approximatel
Slide 19: Compelling Collaboration Rationale
Compelling Roche Maintain Capital Provide Commercial Accelerated Enhancement ©2015 and Foundation infusion shareholders operational Foundation Rationale international platform andfortifies acceleration Medicine, independence with strengthened for Medicine balance exposure Collaboration significant I
Slide 20: Important Information and Where to Find It
Important Information and Where to Find It The tender offer described in this document (the “Offer”) has not yet commenced, and this document is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Foundation Medicine or any other securities. On the c
Foundation Medicine — Merger or Acquisition (January 2015) on 6ix